LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 44

Search options

  1. Article: Evaluation of coronavirus diseases (COVID-19) in terms of epidemiological and clinical features, comorbidities, diagnostic methods, treatment, and mortality.

    Çekmen, Nedim / Ersoy, Zeynep / Günay, Yağız Ilteriş / Ghavam, Amir Aslan / Tufan, Muhammed Yavuz Selim / Şahin, İbrahim Mete

    Journal of education and health promotion

    2022  Volume 11, Page(s) 236

    Abstract: Background: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes COVID-19. On March ... of comorbidities in COVID 19 patients are at higher risk for severe disease, ICU admission, and death. We emphasize ... demographic characteristics, (c) comorbidities, diagnostic methods used, treatment, and outcomes, and (d ...

    Abstract Background: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes COVID-19. On March 11, 2020, the WHO declared it a pandemic. SARS-CoV-2 indicates that it poses a significant threat to public health and global economy. The aim of the study was to determine (a) patient characteristics, (b) demographic characteristics, (c) comorbidities, diagnostic methods used, treatment, and outcomes, and (d) mortality rates of patients.
    Materials and methods: This retrospective cohort study included 352 hospitalized adult patients from Baskent University Hospital in Ankara who were confirmed cases of COVID-19 between March 2020 and March 2021. SPSS v. 14.0 was used for statistical analysis.
    Results: Out of 352 patients, 55 died (males: 37, females: 18), while 297 survived (males: 162, females: 135). The most common comorbidities were hypertension (HT), diabetes mellitus (DM), coronary artery disease (CAD), cancer, Vitamin D deficiency, and chronic obstructive pulmonary disease. Comorbidities associated with mortality rate were obesity (33%) (
    Conclusions: Our study shows that male gender, advanced age, and presence of comorbidities in COVID 19 patients are at higher risk for severe disease, ICU admission, and death. We emphasize that morbidity and mortality can be reduced by early and comprehensive identification of risk factors and the warning systems that will meet the ICU needs of these patients.
    Language English
    Publishing date 2022-07-29
    Publishing country India
    Document type Journal Article
    ZDB-ID 2715449-X
    ISSN 2319-6440 ; 2277-9531
    ISSN (online) 2319-6440
    ISSN 2277-9531
    DOI 10.4103/jehp.jehp_1328_21
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Features, Evaluation and Treatment Coronavirus (COVID-19)

    Cascella, Marco / Rajnik, Michael / Cuomo, Arturo / Dulebohn, Scott C. / Di Napoli, Raffaela

    StatPearls

    Abstract: ... of this illness is now attributed to a novel virus belonging to the coronavirus (CoV) family, COVID-19 On February ... by this new CoV was a "COVID-19," which is the acronym of "coronavirus disease 2019" In the past twenty years ... such as the severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002 to 2003, and H1N1 influenza in 2009, have been recorded Most ...

    Abstract According to the World Health Organization (WHO), viral diseases continue to emerge and represent a serious issue to public health In the last twenty years, several viral epidemics such as the severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002 to 2003, and H1N1 influenza in 2009, have been recorded Most recently, the Middle East respiratory syndrome coronavirus (MERS-CoV) was first identified in Saudi Arabia in 2012 In a timeline that reaches the present day, an epidemic of cases with unexplained low respiratory infections detected in Wuhan, the largest metropolitan area in China's Hubei province, was first reported to the WHO Country Office in China, on December 31, 2019 Published literature can trace the beginning of symptomatic individuals back to the beginning of December 2019 As they were unable to identify the causative agent, these first cases were classified as "pneumonia of unknown etiology " The Chinese Center for Disease Control and Prevention (CDC) and local CDCs organized an intensive outbreak investigation program The etiology of this illness is now attributed to a novel virus belonging to the coronavirus (CoV) family, COVID-19 On February 11, 2020, the WHO Director-General, Dr Tedros Adhanom Ghebreyesus, announced that the disease caused by this new CoV was a "COVID-19," which is the acronym of "coronavirus disease 2019" In the past twenty years, two additional coronavirus epidemics have occurred SARS-CoV provoked a large-scale epidemic beginning in China and involving two dozen countries with approximately 8000 cases and 800 deaths, and the MERS-CoV that began in Saudi Arabia and has approximately 2,500 cases and 800 deaths and still causes as sporadic cases This new virus seems to be very contagious and has quickly spread globally In a meeting on January 30, 2020, per the International Health Regulations (IHR, 2005), the outbreak was declared by the WHO a Public Health Emergency of International Concern (PHEIC) as it had spread to 18 countries with four countries reporting human-to-human transmission An additional landmark occurred on February 26, 2020, as the first case of the disease, not imported from China, was recorded in the United States Initially, the new virus was called 2019-nCoV Subsequently, the task of experts of the International Committee on Taxonomy of Viruses (ICTV) termed it the SARS-CoV-2 virus as it is very similar to the one that caused the SARS outbreak (SARS-CoVs) The CoVs have become the major pathogens of emerging respiratory disease outbreaks They are a large family of single-stranded RNA viruses (+ssRNA) that can be isolated in different animal species For reasons yet to be explained, these viruses can cross species barriers and can cause, in humans, illness ranging from the common cold to more severe diseases such as MERS and SARS Interestingly, these latter viruses have probably originated from bats and then moving into other mammalian hosts — the Himalayan palm civet for SARS-CoV, and the dromedary camel for MERS-CoV — before jumping to humans The dynamics of SARS-Cov-2 are currently unknown, but there is speculation that it also has an animal origin The potential for these viruses to grow to become a pandemic worldwide seems to be a serious public health risk Concerning COVID-19, the WHO raised the threat to the CoV epidemic to the "very high" level, on February 28, 2020 Probably, the effects of the epidemic caused by the new CoV has yet to emerge as the situation is quickly evolving World governments are at work to establish countermeasures to stem possible devastating effects Health organizations coordinate information flows and issues directives and guidelines to best mitigate the impact of the threat At the same time, scientists around the world work tirelessly, and information about the transmission mechanisms, the clinical spectrum of disease, new diagnostics, and prevention and therapeutic strategies are rapidly developing Many uncertainties remain with regard to both the virus-host interac ion and the evolution of the epidemic, with specific reference to the times when the epidemic will reach its peak At the moment, the therapeutic strategies to deal with the infection are only supportive, and prevention aimed at reducing transmission in the community is our best weapon Aggressive isolation measures in China have led to a progressive reduction of cases in the last few days In Italy, in geographic regions of the north of the peninsula, political and health authorities are making incredible efforts to contain a shock wave that is severely testing the health system In the midst of the crisis, the authors have chosen to use the "Statpearls" platform because, within the PubMed scenario, it represents a unique tool that may allow them to make updates in real-time The aim, therefore, is to collect information and scientific evidence and to provide an overview of the topic that will be continuously updated
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #5599
    Database COVID19

    Kategorien

  3. Article ; Online: Evaluation of coronavirus diseases (COVID-19) in terms of epidemiological and clinical features, comorbidities, diagnostic methods, treatment, and mortality

    Nedim Cekmen / Zeynep Ersoy / Yağılz İlteriş Günay / Amir Aslan Ghavam / Muhammed Yavuz Selim Tufan / İbrahim Mete Şahin

    Journal of Education and Health Promotion, Vol 11, Iss 1, Pp 236-

    2022  Volume 236

    Abstract: BACKGROUND: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes COVID-19. On March ... of comorbidities in COVID 19 patients are at higher risk for severe disease, ICU admission, and death. We emphasize ... demographic characteristics, (c) comorbidities, diagnostic methods used, treatment, and outcomes, and (d ...

    Abstract BACKGROUND: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes COVID-19. On March 11, 2020, the WHO declared it a pandemic. SARS-CoV-2 indicates that it poses a significant threat to public health and global economy. The aim of the study was to determine (a) patient characteristics, (b) demographic characteristics, (c) comorbidities, diagnostic methods used, treatment, and outcomes, and (d) mortality rates of patients. MATERIALS AND METHODS: This retrospective cohort study included 352 hospitalized adult patients from Baskent University Hospital in Ankara who were confirmed cases of COVID-19 between March 2020 and March 2021. SPSS v. 14.0 was used for statistical analysis. RESULTS: Out of 352 patients, 55 died (males: 37, females: 18), while 297 survived (males: 162, females: 135). The most common comorbidities were hypertension (HT), diabetes mellitus (DM), coronary artery disease (CAD), cancer, Vitamin D deficiency, and chronic obstructive pulmonary disease. Comorbidities associated with mortality rate were obesity (33%) (P = 0.118), Vitamin D deficiency (28%) (P = 0.009), DM (25%) (P = 0.004), CAD (21.2%) (P = 0.142), cancer (20.9%) (P = 0.084), and HT (16.6%) (P = 0.90). Normal ward admission resulted in death in 67.3% and survival in 93.9% (P = 0.001), intensive care unit (ICU) admission resulted in death in 69.1% and survival in 18.5% (P = 0.001), and oxygen therapy was used in 80% death and survival in 39.4% (P = 0.001). CONCLUSIONS: Our study shows that male gender, advanced age, and presence of comorbidities in COVID 19 patients are at higher risk for severe disease, ICU admission, and death. We emphasize that morbidity and mortality can be reduced by early and comprehensive identification of risk factors and the warning systems that will meet the ICU needs of these patients.
    Keywords comorbidities ; covid-19 ; demography ; early identification ; morbidity ; mortality ; Special aspects of education ; LC8-6691 ; Public aspects of medicine ; RA1-1270
    Subject code 610
    Language English
    Publishing date 2022-01-01T00:00:00Z
    Publisher Wolters Kluwer Medknow Publications
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  4. Article: Features, Evaluation and Treatment Coronavirus (COVID-19) Discussing the ABCs of Health Security-Antibiotic Resistance, Biothreats, and Coronavirus

    Cascella, M. / Rajnik, M. / Cuomo, A. / Dulebohn, S. C. / Di Napoli, R. / Desai, A. N.

    StatPearls

    Abstract: ... of this illness is now attributed to a novel virus belonging to the coronavirus (CoV) family, COVID-19 On February ... by this new CoV was a "COVID-19," which is the acronym of "coronavirus disease 2019" In the past twenty years ... such as the severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002 to 2003, and H1N1 influenza in 2009, have been recorded Most ...

    Abstract According to the World Health Organization (WHO), viral diseases continue to emerge and represent a serious issue to public health In the last twenty years, several viral epidemics such as the severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002 to 2003, and H1N1 influenza in 2009, have been recorded Most recently, the Middle East respiratory syndrome coronavirus (MERS-CoV) was first identified in Saudi Arabia in 2012 In a timeline that reaches the present day, an epidemic of cases with unexplained low respiratory infections detected in Wuhan, the largest metropolitan area in China's Hubei province, was first reported to the WHO Country Office in China, on December 31, 2019 Published literature can trace the beginning of symptomatic individuals back to the beginning of December 2019 As they were unable to identify the causative agent, these first cases were classified as "pneumonia of unknown etiology " The Chinese Center for Disease Control and Prevention (CDC) and local CDCs organized an intensive outbreak investigation program The etiology of this illness is now attributed to a novel virus belonging to the coronavirus (CoV) family, COVID-19 On February 11, 2020, the WHO Director-General, Dr Tedros Adhanom Ghebreyesus, announced that the disease caused by this new CoV was a "COVID-19," which is the acronym of "coronavirus disease 2019" In the past twenty years, two additional coronavirus epidemics have occurred SARS-CoV provoked a large-scale epidemic beginning in China and involving two dozen countries with approximately 8000 cases and 800 deaths, and the MERS-CoV that began in Saudi Arabia and has approximately 2,500 cases and 800 deaths and still causes as sporadic cases This new virus seems to be very contagious and has quickly spread globally In a meeting on January 30, 2020, per the International Health Regulations (IHR, 2005), the outbreak was declared by the WHO a Public Health Emergency of International Concern (PHEIC) as it had spread to 18 countries with four countries reporting human-to-human transmission An additional landmark occurred on February 26, 2020, as the first case of the disease, not imported from China, was recorded in the United States Initially, the new virus was called 2019-nCoV Subsequently, the task of experts of the International Committee on Taxonomy of Viruses (ICTV) termed it the SARS-CoV-2 virus as it is very similar to the one that caused the SARS outbreak (SARS-CoVs) The CoVs have become the major pathogens of emerging respiratory disease outbreaks They are a large family of single-stranded RNA viruses (+ssRNA) that can be isolated in different animal species For reasons yet to be explained, these viruses can cross species barriers and can cause, in humans, illness ranging from the common cold to more severe diseases such as MERS and SARS Interestingly, these latter viruses have probably originated from bats and then moving into other mammalian hosts — the Himalayan palm civet for SARS-CoV, and the dromedary camel for MERS-CoV — before jumping to humans The dynamics of SARS-Cov-2 are currently unknown, but there is speculation that it also has an animal origin The potential for these viruses to grow to become a pandemic worldwide seems to be a serious public health risk Concerning COVID-19, the WHO raised the threat to the CoV epidemic to the "very high" level, on February 28, 2020 Probably, the effects of the epidemic caused by the new CoV has yet to emerge as the situation is quickly evolving World governments are at work to establish countermeasures to stem possible devastating effects Health organizations coordinate information flows and issues directives and guidelines to best mitigate the impact of the threat At the same time, scientists around the world work tirelessly, and information about the transmission mechanisms, the clinical spectrum of disease, new diagnostics, and prevention and therapeutic strategies are rapidly developing Many uncertainties remain with regard to both the virus-host interaction and the evolution of the epidemic, with specific reference to the times when the epidemic will reach its peak At the moment, the therapeutic strategies to deal with the infection are only supportive, and prevention aimed at reducing transmission in the community is our best weapon Aggressive isolation measures in China have led to a progressive reduction of cases in the last few days In Italy, in geographic regions of the north of the peninsula, political and health authorities are making incredible efforts to contain a shock wave that is severely testing the health system In the midst of the crisis, the authors have chosen to use the "Statpearls" platform because, within the PubMed scenario, it represents a unique tool that may allow them to make updates in real-time The aim, therefore, is to collect information and scientific evidence and to provide an overview of the topic that will be continuously updated
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #12230
    Database COVID19

    Kategorien

  5. Article: [Features of echocardiographic examination in patients with COVID-19].

    Golukhova, E Z / Slivneva, I V / Mamalyga, M L / Alekhin, M N

    Kardiologiia

    2023  Volume 63, Issue 5, Page(s) 3–11

    Abstract: ... of the treatment for patients with COVID-19. For these reasons, EchoCG should serve as an additional method ... for early identification of signs of systolic dysfunction and risk stratification in patients with COVID-19 ... of a new paradigm in diagnosis and treatment. Studies performed during the pandemic have demonstrated ...

    Abstract Novel coronavirus infection has become one of urgent health problems of the 21st century. The associated disorders often result in the development of cardiopulmonary pathology, which requires creation of a new paradigm in diagnosis and treatment. Studies performed during the pandemic have demonstrated an important role of echocardiography (EchoCG) in diagnosis of right ventricular (RV) dysfunction in patients with respiratory insufficiency in COVID-19. The analysis of EchoCG parameters with a high prognostic value showed that in EchoCG, a special attention should be paid to right heart dimensions, RV contractility, and pulmonary artery (PA) systolic pressure, which are the most sensitive indexes of RV afterload and indirect markers of pulmonary disease severity. RV FAC can be recommended for evaluation of the RV systolic function as the most informative variable. Also, it was demonstrated that the RV longitudinal strain has an additional significance for early identification of signs of systolic dysfunction and risk stratification in patients with COVID-19. In addition to the effectiveness and reproducibility of this method, an important advantage of EchoCG is its availability, possibility of saving images for remote interpretation by other specialists, and tracking changes in morphological and functional parameters of the heart. Thus, the analysis of international literature suggests that EchoCG plays an important role in prediction of severe cardiopulmonary disorders and timely selection of the treatment for patients with COVID-19. For these reasons, EchoCG should serve as an additional method of clinical evaluation, particularly in persons with moderate or severe disease.
    MeSH term(s) Humans ; COVID-19 ; Reproducibility of Results ; Echocardiography ; Heart ; SARS-CoV-2
    Language Russian
    Publishing date 2023-05-31
    Publishing country Russia (Federation)
    Document type English Abstract ; Journal Article
    ZDB-ID 131029-x
    ISSN 0022-9040
    ISSN 0022-9040
    DOI 10.18087/cardio.2023.5.n1806
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Evaluation of Clinical Features and Olfactory Functions in COVID-19: A Multicentre Study.

    Taş, Burak Mustafa / Alpaydın, Turgay / Akçalı, Sinem / Kaygusuz, Sedat / Özlük Erol, Özlem / Şencan, Ziya / Cömert, Ela / Bayar Muluk, Nuray / Özel, Gökçe

    Cureus

    2023  Volume 15, Issue 6, Page(s) e40027

    Abstract: ... fever, follow-up place, and treatment schemes. Conclusion As a result, negative effects of COVID-19 ... Introduction Coronavirus Disease-2019 (COVID-19) causes olfactory loss one of the initial ... admission, fever, follow-up place, and treatment schemes were noted. Results There was a significant ...

    Abstract Introduction Coronavirus Disease-2019 (COVID-19) causes olfactory loss one of the initial diagnostic criteria. The brief smell identification test (BSIT) is an objective test frequently used in olfactory dysfunction. This study aimed to observe the changes in olfactory functions and clinical features in a short time in COVID-19. Methods In this prospective study involving 64 patients, the BSIT was performed at two different times; at the time of first application and on the 14th day. Demographic features, laboratory findings, body mass index (BMI), blood oxygen saturation values (SpO2), complaints at first admission, fever, follow-up place, and treatment schemes were noted. Results There was a significant difference between the BSIT scores at the first admission and when the polymerase chain reaction (PCR) became negative on the 14th day (p<0.001). Low oxygen saturation values at first admission were associated with low BSIT scores. No relationship was found between olfactory functions and complaints at admission, fever, follow-up place, and treatment schemes. Conclusion As a result, negative effects of COVID-19 on olfactory functions have been demonstrated even in the short follow-up period. In addition, low saturation values at first admission were associated with low BSIT scores.
    Language English
    Publishing date 2023-06-06
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2747273-5
    ISSN 2168-8184
    ISSN 2168-8184
    DOI 10.7759/cureus.40027
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Clinical features of multisystem inflammatory syndrome in children.

    Roberts, Jordan E / Henderson, Lauren A

    Current opinion in rheumatology

    2021  Volume 33, Issue 5, Page(s) 378–386

    Abstract: ... appropriate evaluation and treatment. ... Purpose of review: To review diagnosis, clinical characteristics and treatment of multisystem ... should be considered as initial adjunctive treatment for patients with severe manifestations or ...

    Abstract Purpose of review: To review diagnosis, clinical characteristics and treatment of multisystem inflammatory syndrome in children (MIS-C) associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
    Recent findings: MIS-C emerged in spring 2020 as a hyperinflammatory syndrome following SARS-CoV-2 exposure in children. Despite growing awareness of MIS-C, diagnosis remains challenging due to the range of phenotypes and severity. Fever accompanied by shock, cardiac dysfunction, gastrointestinal symptoms, or mucocutaneous signs suggestive of Kawasaki disease, especially in the presence of known or suspected coronavirus disease 2019 exposure, should trigger consideration of MIS-C. However, clinical presentations are highly varied and may overlap with other infectious diseases. Clinicians must maintain a high index of suspicion for MIS-C and be aware that patients may develop coronary artery aneurysms and myocarditis even with few or no Kawasaki disease symptoms. More precise diagnostic criteria and specific biomarkers are needed to aid diagnosis. Intravenous immunoglobulin (IVIG) is first-line therapy, and steroids should be considered as initial adjunctive treatment for patients with severe manifestations or other risk factors. Prompt treatment is essential, as patients may worsen acutely, though overall prognosis is reassuring.
    Summary: MIS-C associated with SARS-CoV-2 has varied clinical manifestations. Clinicians must be aware of the common presentation and potential for decompensation and cardiac sequalae to guide appropriate evaluation and treatment.
    MeSH term(s) COVID-19 ; Humans ; Mucocutaneous Lymph Node Syndrome/diagnosis ; Mucocutaneous Lymph Node Syndrome/epidemiology ; Mucocutaneous Lymph Node Syndrome/therapy ; SARS-CoV-2 ; Systemic Inflammatory Response Syndrome
    Language English
    Publishing date 2021-07-15
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Review
    ZDB-ID 1045317-9
    ISSN 1531-6963 ; 1040-8711
    ISSN (online) 1531-6963
    ISSN 1040-8711
    DOI 10.1097/BOR.0000000000000818
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Clinical Features, Diagnostic Evaluation, and Management of COVID-19 Patients.

    Mallick, Rahul / Duttaroy, Asim K

    Advances in experimental medicine and biology

    2022  Volume 1353, Page(s) 1–22

    Abstract: ... and confirmed COVID-19.: Results: The case fatality rate is estimated at around 3%. Diagnosis is ... distress syndrome (ARDS), and multiple organ dysfunction syndromes (MODS).: Conclusion: Treatment is ... coronavirus pandemic has posed a global health emergency.: Methods: We focused on clinical features ...

    Abstract Introduction: Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2)-associated coronavirus pandemic has posed a global health emergency.
    Methods: We focused on clinical features, diagnostic evaluation, management, infection prevention, and safe handling of deceased bodies with suspected and confirmed COVID-19.
    Results: The case fatality rate is estimated at around 3%. Diagnosis is by the demonstration of the virus in respiratory secretions by RT-PCR mainly. Common laboratory findings include average/low white cell counts with elevated C-reactive protein (CRP). The disease is mild in most people; in some (usually the elderly and those with comorbidities), it may progress to pneumonia, acute respiratory distress syndrome (ARDS), and multiple organ dysfunction syndromes (MODS).
    Conclusion: Treatment is primarily supportive; the role of antiviral agents is yet to be established. Prevention entails home isolation of suspected cases and those with mild illnesses and strict infection control measures at hospitals that include contact and droplet precautions.
    MeSH term(s) Aged ; Antiviral Agents/therapeutic use ; COVID-19 ; Humans ; Pandemics ; Respiratory Distress Syndrome ; SARS-CoV-2
    Chemical Substances Antiviral Agents
    Language English
    Publishing date 2022-02-09
    Publishing country United States
    Document type Journal Article
    ISSN 2214-8019 ; 0065-2598
    ISSN (online) 2214-8019
    ISSN 0065-2598
    DOI 10.1007/978-3-030-85113-2_1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Clinical characteristics and computed tomographical features of pulmonary thromboembolic disease associated with COVID-19 infection: A tertiary hospital analysis.

    Tan, T L / Illa, N E / Ting, S Y / Hwong, P L / Azmel, A / Shunmugarajoo, A / Chiew, S C

    The Medical journal of Malaysia

    2023  Volume 78, Issue 2, Page(s) 155–162

    Abstract: Introduction: The co-existence of coronavirus disease 2019 (COVID-19) and pulmonary thromboembolic ... 0.027) and ferritin levels (median 1469 vs. 1229; p=0.024) among them. Evaluation of CT features ... associated with COVID-19 infection and (2) to compare these parameters with those COVID-19 patients ...

    Abstract Introduction: The co-existence of coronavirus disease 2019 (COVID-19) and pulmonary thromboembolic (PTE) disease poses a great clinical challenge. To date, few researches have addressed this important clinical issue among the South-East Asian populations. The objectives of this study were as follow: (1) to describe the clinical characteristics and computed tomographical (CT) features of patients with PTE disease associated with COVID-19 infection and (2) to compare these parameters with those COVID-19 patients without PTE disease.
    Materials and methods: This cross-sectional study with retrospective record review was conducted in Hospital Tengku Ampuan Rahimah, Selangor, Malaysia. We included all hospitalised patients with confirmed COVID-19 infection who had undergone CT pulmonary angiogram (CTPA) examinations for suspected PTE disease between April 2021 and May 2021. Clinical data and laboratory data were extracted by trained data collectors, whilst CT images retrieved were analysed by a senior radiologist. Data analysis was performed using Statistical Package for the Social Sciences (SPSS) version 20.
    Results: We studied 184 COVID-19 patients who were suspected to have PTE disease. CTPA examinations revealed a total of 150 patients (81.5%) suffered from concomitant PTE disease. Among the PTE cohort, the commonest comorbidities were diabetes mellitus (n=78, 52.0%), hypertension (n=66, 44.0%) and dyslipidaemia (n=25, 16.7%). They were generally more ill than the non-PTE cohort as they reported a significantly higher COVID-19 disease category during CTPA examination with p=0.042. Expectedly, their length of both intensive care unit stays (median number of days 8 vs. 3; p=0.021) and hospital stays (median number of days 14.5 vs. 12; p=0.006) were significantly longer. Intriguingly, almost all the subjects had received either therapeutic anticoagulation or thromboprophylactic therapy prior to CTPA examination (n=173, 94.0%). Besides, laboratory data analysis identified a significantly higher peak C-reactive protein (median 124.1 vs. 82.1; p=0.027) and ferritin levels (median 1469 vs. 1229; p=0.024) among them. Evaluation of CT features showed that COVID-19 pneumonia pattern (p<0.001) and pulmonary angiopathy (p<0.001) were significantly more profound among the PTE cohort. To note, the most proximal pulmonary thrombosis was located in the segmental (n=3, 2.0%) and subsegmental pulmonary arteries (n=147, 98.0%). Also, the thrombosis predominantly occurred in bilateral lungs with multilobar involvement (n=95, 63.3%).
    Conclusion: Overall, PTE disease remains prevalent among COVID-19 patients despite timely administration of thromboprophylactic therapy. The presence of hyperinflammatory activities, unique thrombotic locations as well as concurrent pulmonary parenchyma and vasculature aberrations in our PTE cohort implicate immunothrombosis as the principal mechanism of this novel phenomenon. We strongly recommend future researchers to elucidate this important clinical disease among our post- COVID vaccination populations.
    MeSH term(s) Humans ; COVID-19/complications ; COVID-19/diagnostic imaging ; Tertiary Care Centers ; Retrospective Studies ; Cross-Sectional Studies ; Neovascularization, Pathologic ; Pulmonary Circulation ; Pulmonary Embolism/diagnostic imaging ; Pulmonary Embolism/etiology ; Tomography, X-Ray Computed/methods ; Lung Diseases ; Thrombosis
    Language English
    Publishing date 2023-03-29
    Publishing country Malaysia
    Document type Journal Article
    ZDB-ID 604286-7
    ISSN 0300-5283
    ISSN 0300-5283
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Multistage CT features of coronavirus disease 2019.

    Zhong, Zheng / Hu, Ying / Yu, Qizhi / Li, Yuxin / Li, Peng / Huang, Wei / Liu, Jingui / Liu, Jun / Xie, Xingzhi / Zhao, Wei

    Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences

    2020  Volume 45, Issue 3, Page(s) 250–256

    Abstract: Objectives: To determine imaging features of coronavirus disease 2019 (COVID-19) in different ... and the evaluation for the therapeutic effect on COVID-19 patient. ... stages, and to provide foundations for early diagnosis and treatment.: Methods: CT image data of 187 ...

    Title translation 2019冠状病毒病多阶段CT影像学特征.
    Abstract Objectives: To determine imaging features of coronavirus disease 2019 (COVID-19) in different stages, and to provide foundations for early diagnosis and treatment.
    Methods: CT image data of 187 COVID-19 patients were analyzed in the period of hospitalization. CT scanning was performed on admission and repeated every 3 days. The improvement time of clinical symptoms and the image changes of follow-up CT were statistically analyzed.
    Results: All 187 patients' nucleic acid test were positive to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The early CT images of lung in 187 cases (100%) showed multiple patchy and ground-glass opacities with fine mesh and consolidation shade, which mainly distributed in pulmonary band or under the pleura. In the progressive stage, the pulmonary lesions in 146 cases (78.1%) were mainly consolidation, accompanied by air bronchogram, thickening of blood vessels, and interstitial changes. Severe pulmonary CT images in 15 cases (8%) showed diffuse lesions in both lungs, displaying consolidation, or "white lung". The CT imaging features in 185 cases (98.9%) at the absorptive period showed that the lesions diminished and fibrogenesis. The imaging features of 6 times of lung CT examination in one case showed continuous progress. The original lesion in one case was obviously absorbed, but new lesions appeared under the pleura of both lungs at the third review of CT scanning. The changes of CT imaging lesions during follow-up were significantly different in different clinical symptoms improvement time (
    Conclusions: Images of COVID-19 in various stages have special characteristics. The change of clinical symptoms is synchronous with the change of reexamination CT. Follow-up CT can reflect the trend of clinical changes. Repeat CT examination plays an important role in the early clinical diagnosis and the evaluation for the therapeutic effect on COVID-19 patient.
    MeSH term(s) Betacoronavirus ; COVID-19 ; Coronavirus Infections/diagnostic imaging ; Humans ; Pandemics ; Pneumonia, Viral/diagnostic imaging ; SARS-CoV-2 ; Tomography, X-Ray Computed
    Keywords covid19
    Language Chinese
    Publishing date 2020-06-23
    Publishing country China
    Document type Journal Article
    ZDB-ID 2168533-2
    ISSN 1672-7347
    ISSN 1672-7347
    DOI 10.11817/j.issn.1672-7347.2020.200144
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top